Dossier
George Yancopoulos
Coverage of George Yancopoulos in the Nexus archive.
- Regeneron Pharmaceuticals concealed cancer drug trial risks from public, investors say
Regeneron Pharmaceuticals faces investor claims of inflating stock prices by overstating the potential of a skin cancer treatment's clinical trial, which later failed to meet approval benchmarks. Investors allege the company minimized risks of trial delays while describing the drug combination as a 'potential blockbuster,' leading to significant stock price declines after the trial's failure was disclosed.
- Regeneron president followed in role model’s footsteps to achieve the American dream — despite English not being his first language
George Yancopoulos co-founded a remarkably successful company and hired his scientific hero. The article highlights his journey toward achieving the American dream despite English not being his first language.